Distinguishing Radiesse treatment areas from approved indications

This article discusses the source author’s earlier literature, cases and experiences. Research populations and limitations matter; individual diagnosis and treatment require clinical assessment.

Treatment areas, research and approval

The source starts with Radiesse’s early US approval history and discusses later research in facial and body sites. A growing research literature does not mean every described site is approved or offered by the current clinic.

Volume and tissue-response discussions

CaHA microspheres are suspended in a CMC gel. Dilution changes physical properties, but a research description is not a universal preparation instruction.

The source describes undiluted material in volume and contour discussions, including nasolabial folds, cheeks and jawline. Actual indications and technique require product-specific assessment.

The source discusses diluted CaHA in skin-laxity research, including the neck, chest and body. Its ≥1:1 terminology and claimed tissue effects require comparison with the study and labeling.

Reference cited: Guida and Galadari, International Journal of Dermatology. 2024;63(7):881–889, a review of body applications. It summarizes research rather than approving each use.

Facial sites discussed by the source

The source cites a 2024 systematic review of facial applications by Guida and colleagues.

Cheek and midface volume were discussed, including undiluted and 1:1 examples. These are not general patient instructions.

The source cites a jawline RCT by Green et al., 2024, with 48–60-week follow-up and mentions a US jawline indication. Current, product-specific US and Korean labeling must be checked separately.

The source discusses marionette and pre-jowl areas. Descriptions such as high efficacy depend on the underlying evidence and outcome definition.

The temple has important vascular anatomy and requires careful risk assessment; cannula use is not a guarantee of safety.

Reference cited: Guida S, et al. International Journal of Dermatology. 2024;63:150–160. The populations, sites and evidence quality need to be distinguished.

Hands: distinguish approval from research

The source discusses US approval for the dorsum of the hand. It does not retain the claim that this is the only body indication without checking current labeling. US and Korean approvals differ.

Thin skin and nearby tendons and vessels are relevant to hand assessment.

Body research

The source describes Guida and Galadari’s review as extending the facial literature to body research; any claim of being the first review requires checking.

Upper-arm and thigh laxity were among the topics discussed. The original’s shallow-injection language is not a patient instruction.

Abdominal and buttock laxity were discussed with limited randomized-trial evidence.

Neck and chest studies require attention to movement, tissue thickness and nodule risk.

The source calls for further research, particularly controlled studies of body applications.

Research topics by site

| Areas discussed | Research topic | | --- | --- | | Nasolabial region, cheeks and jawline | Wrinkles, volume and contour | | Dorsal hands | Volume loss | | Neck, chest, arms, thighs and abdomen | Skin-laxity research |

This table is not a list of approved or currently offered services. Dilution and injection-plane instructions were omitted.

Keep the evidence and labeling separate

CaHA has been investigated at several sites, with different purposes and methods. Individual indications, evidence and local product labeling must be checked before treatment.

This article introduces the source’s cited literature, including Guida et al. and Green et al., rather than guaranteeing a result or advertising every described application.

Materials linked by the source

• Source material 1